New ad hoc reporting tool offers easy user interface to facilitate more in-depth data capture and broad graphical presentations
San Ramon, CA – March 30, 2009 –
Nextrials, Inc., a leader in clinical research software and services, today announced that its award-winning Prism® data capture and clinical trial management platform has increased its report generation functionality to deliver more powerful data mining capabilities to customers. With the improved ad hoc reporting feature, users can now collect, summarize and export data from tables within a single study or across multiple studies, creating efficiencies that save time and lower study costs. Its user-friendly graphical interface also includes advanced interactive data view formats, such as heat maps, in addition to bar graphs, pie charts and other standard visual templates.
These new reporting features are tightly integrated within Prism (no separate log-ins are required). Product highlights are:
- an intuitive user interface
- preview panes to help users visualize reports in progress
- broad, interactive graphical tools
- enhanced export capabilities
- concomitant medication and adverse event coding data integration
Visitors to the 18th annual Partnerships with CROs, being held April 28-30 at the Rosen Shingle Creek Hotel in Orlando, FL, can see a demonstration of Prism with its enhanced reporting functionality in booth #601.
“Prism continues to evolve in tandem with our customers’ needs,” noted Robert Barr, chief technology officer at Nextrials. “With the growing complexity of clinical trials, it’s important for researchers to be able to generate reports customized for numerous audiences, ranging from safety analysts to clinicians. Prism’s enhanced reporting capabilities make it easier to both compile trial data and drill down on data points of interest, providing better visibility of study results, and reducing the opportunity for error.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit
www.nextrials.com
or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at
http://pharmavoice.com/podcasts
.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.